Lyudmila Bazhenova Selected Research

Lyudmila Bazhenova Research Topics

Disease

40	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 04/2010
31	Neoplasms (Cancer) 03/2024 - 01/2013
18	Lung Neoplasms (Lung Cancer) 01/2024 - 04/2011
7	Disease Progression 07/2023 - 02/2006
4	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2014
4	Diarrhea 01/2023 - 10/2019
4	Circulating Neoplastic Cells 02/2015 - 02/2012
3	Vomiting 01/2023 - 02/2021
2	Malignant Mesothelioma 03/2024 - 12/2014
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2024 - 01/2018
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 02/2012
2	Exanthema (Rash) 07/2023 - 01/2018
2	Pulmonary Embolism 07/2023 - 12/2016
2	Nausea 01/2023 - 01/2023
2	Fatigue 01/2023 - 01/2018
2	Adenocarcinoma of Lung 03/2022 - 09/2017
2	Hypertension (High Blood Pressure) 01/2020 - 10/2019
1	Small Cell Carcinoma 04/2024
1	Inflammation (Inflammations) 01/2024
1	Long QT Syndrome 01/2024
1	Bradycardia 07/2023
1	Pericardial Effusion 07/2023
1	Pleural Effusion (Pleural Effusions) 07/2023
1	Colorectal Neoplasms (Colorectal Cancer) 10/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2022
1	Body Weight (Weight, Body) 01/2022
1	Hyperglycemia 02/2021
1	Hyponatremia 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Proteinuria 10/2019
1	Epilepsy (Aura) 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Acne Vulgaris 01/2018
1	Carcinogenesis 01/2018

Drug/Important Bio-Agent (IBA)

10	ErbB Receptors (EGF Receptor)IBA 01/2023 - 03/2015
7	Tyrosine Kinase InhibitorsIBA 07/2023 - 12/2016
7	Phosphotransferases (Kinase)IBA 10/2022 - 04/2010
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
5	NivolumabIBA 01/2024 - 01/2021
5	PlatinumIBA 01/2023 - 02/2021
4	IpilimumabIBA 01/2024 - 09/2021
4	Proteins (Proteins, Gene)FDA Link 01/2024 - 07/2009
4	Alanine Transaminase (SGPT)IBA 01/2023 - 12/2016
4	Immune Checkpoint InhibitorsIBA 11/2022 - 11/2017
4	TropomyosinIBA 01/2022 - 01/2018
3	adagrasibIBA 01/2023 - 01/2022
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 01/2020
3	osimertinibIBA 01/2019 - 12/2016
2	alectinibIBA 07/2023 - 10/2021
2	CrizotinibIBA 07/2023 - 12/2010
2	trastuzumab deruxtecanIBA 05/2023 - 01/2022
2	mobocertinibIBA 01/2023 - 01/2021
2	entrectinibIBA 05/2022 - 01/2022
2	amivantamab-vmjwIBA 01/2022 - 01/2022
2	B7-H1 AntigenIBA 01/2022 - 01/2017
2	tyrosine receptor (receptor, tyrosine)IBA 01/2022 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 01/2021
2	Pemetrexed (MTA)FDA Link 02/2021 - 12/2014
2	selpercatinibIBA 01/2021 - 01/2020
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 01/2017
2	AntibodiesIBA 01/2018 - 08/2014
2	Circulating Tumor DNAIBA 10/2017 - 09/2017
2	Keratins (Keratin)IBA 01/2017 - 08/2014
1	repotrectinibIBA 01/2024
1	Anaplastic Lymphoma KinaseIBA 07/2023
1	TabletsIBA 01/2023
1	glycolic acid (glycolate)IBA 01/2023
1	EnzymesIBA 01/2023
1	ElectrolytesIBA 01/2023
1	AntiemeticsIBA 01/2023
1	SaltsIBA 01/2023
1	glesatinibIBA 01/2023
1	SuspensionsIBA 01/2023
1	Capsules (Microcapsules)IBA 01/2023
1	c-Mer Tyrosine KinaseIBA 10/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	sitravatinibIBA 10/2022
1	brigatinibIBA 09/2022
1	Axitinib (AG 013736)IBA 01/2022
1	palbociclibIBA 01/2022
1	avelumabIBA 01/2022
1	human ERBB2 proteinIBA 01/2022
1	pembrolizumabIBA 01/2022
1	rociletinibIBA 02/2021
1	Docetaxel (Taxotere)FDA Link 02/2021
1	Gemcitabine FDA Link 02/2021
1	DV281IBA 01/2021
1	veliparibIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	Bevacizumab (Avastin)FDA Link 10/2019
1	agerafenibIBA 01/2019
1	eosinylphosphatidylethanolamine (EOPE)IBA 01/2019
1	Cetuximab (Erbitux)FDA Link 01/2018
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2018

Therapy/Procedure

23	Therapeutics 03/2024 - 02/2006
8	Drug Therapy (Chemotherapy) 01/2022 - 09/2014
7	Immunotherapy 01/2024 - 01/2017
5	Radiotherapy 01/2018 - 04/2011
1	Diet Therapy (Therapy, Diet) 01/2023
1	Chemoradiotherapy 01/2021